论文部分内容阅读
目的 探讨慢性肝病患者内毒素血症 (Endotoxemia,ETM )的发生率及临床意义 ,并观察丽珠肠乐治疗肝病合并ETM的转阴率。方法 应用偶氮基质显色法鲎试验方法检测 110例慢性肝病患者血清内毒素 (ET)水平 ,并选择 80例慢性肝病合并ETM患者 ,随机分丽珠肠乐治疗组 (n =4 0 )和对照组 (n =4 0 )。结果 慢性肝病患者血清ET水平明显高于正常对照组 ,以重症肝炎最高。重症肝炎组血清胆红素>342 μmol/L、白蛋白 <30g/L及PT活动度 <30 %时ETM发生率为 10 0 % ,ET水平高于血清胆红素 (171μmol/L 30 g/L及PT活动度 >30 %的患者。慢性肝病腹水患者腹水与血清ET水平均升高 ,分别为(315± 80 )与 (342± 83)ng/L。服丽珠肠乐治疗后 ,慢性肝病合并ETM组的转阴率较对照组为高。结论 慢性肝病患者ETM发生率高 ,肠道微生态调节剂丽珠肠乐能有效地减轻或清除ETM。
Objective To investigate the incidence and clinical significance of endotoxemia (ETM) in patients with chronic liver disease and to observe the negative conversion rate of Lizhu Pianle in the treatment of liver disease complicated with ETM. Methods Serum endotoxin (ET) level was measured in 110 patients with chronic liver disease by azo-substrate chromogenic assay method. Eighty patients with chronic liver disease and ETM were randomly divided into three groups: control group (n = 40) and control group Control group (n = 40). Results Serum ET levels in patients with chronic liver disease were significantly higher than those in the normal control group, with the highest in severe hepatitis. Serum bilirubin> 342 μmol / L, albumin <30 g / L and PT <30% in patients with severe hepatitis were associated with a 10% incidence of ETM and a higher ET level than serum bilirubin (171 μmol / L < 342 μmol / L), albumin> 30 g / L, and PT activity> 30%. Ascites in patients with chronic liver disease and serum ET levels were elevated (315 ± 80) and (342 ± 83) ng / L. After taking Lizhu Renle treatment, the negative conversion rate of chronic liver disease combined ETM group was higher than that of control group. Conclusion The incidence of ETM in patients with chronic liver disease is high, and intestinal microecological regulator Lizhu Changle can effectively reduce or eliminate ETM.